PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CHOLECALCIFEROL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 37 records · Page 2Linked to original sources

Evaluation of cholecalciferol sources using broiler chick bioassays.

Three experiments were conducted to test the potencies of nine sources of cholecalciferol using a chick bioassay. The tested products were compared with a Sigma Reference Standard (SRS). All of the diets fed to the chicks were prepared from corn-soybean meal. Each of the products was in premix form containing cholecalciferol. Their physical characteristics reflected the methods used to produce the premixes. They were categorized as spray-dried or drum-dried in the beadlet or flake form. Basal diets without cholecalciferol were used in all experiments. For Experiments 1 and 2, the designs were a 2 x 3 factorial arrangement using three different cholecalciferol products and two levels of 200 and 400 IU/kg dietary cholecalciferol. For both experiments, three additional SRS levels of 600, 800, and 1,000 IU/kg were included in the studies as positive controls as there is a possibility that the cholecalciferol products being tested may exhibit activity higher than the amount stated. In Experiment 3, a 3 x 4 factorial arrangement was used, which was represented by three cholecalciferol products and four levels of dietary cholecalciferol at 150, 300, 600, and 1,200 IU/kg. By using the slope ratio analysis, the potencies of the products from the three experiments were between 86 and 118%. In Experiment 3, the requirement of chicks for cholecalciferol using the three tested products, as determined by a nonlinear regression model based on bone ash, were 843+/-85, 911+/-106, and 986+/-131 IU/kg of diet as compared with 915+/-82 IU/kg when using the SRS. The results from these studies indicate that the chemical assays used to determine the cholecalciferol activity of these products were very reliable.

Animal Feed↗

Quantitative studies of the interaction of cholecalciferol ((vitamin D3) and its metabolites with different genetic variants of the serum binding protein for these sterols.

Cholecalciferol (vitamin D3) and its 25-hydroxy metabolite are transported in plasma bound to a specific protein, the binding protein for cholecalciferol and its metabolites (DBP). DBP is identical with the group-specific component (Gc) proteins, which are known to display genetic polymorphism. Studies were conducted to explore whether or not major differences in the transport of cholecalciferol and its biological metabolites might exist among persons with different Gc phenotypes. Detailed quantitative studies were first carried out on the interaction of 25(OH)D3 with DBP in 21 different samples of serum, representing eight different Gc phenotypes. The studies used a filter disc assay method that provided highly reproducible quantitative results with cholecalciferol-related sterols. The Gc phenotypes studied included the three common types (Gc 1-1, 2-1, and 2-2) and several uncommon genetic variants (Gc Ab-Ab, Ab-1, Ab-2, Chip-1, and Chip-2). The binding affinities for 25(OH)D3 observed with these different sera were all fairly similar to each other. More extensive studies were then conducted to compare the binding of four cholecalciferol-related sterols to each of three genetic variants of DBP, by using sera from homozygous persons with the Gc 1-1, Gc 2-2 and Gc Ab-Ab phenotypes. The ligands tested included cholecalciferol, 25(OH)D3, 1,25(OH)2D3, and 24(R) 25(OH)2D3. The affinities of the three genetic types of DBP/Gc protein were found to be similar for each of the four cholecalciferol-related sterols. The apparent association constants for 25(OH)D3 and 24,25(OH)2D3 were similar (approx. 1--2 x 10(8) M-1); lesser affinities were observed for 1,25(OH)2D3 (kA approx. 1 x 10(7) M-1) and for cholecalciferol (kA approx. 3--4 x 10(5) M-1). Thus the common genetic variants of DBP/Gc protein, and the uncommon genetic variants studied here, all appear to have similar binding properties for cholecalciferol and its several metabolites.

Alpha-Globulins↗

Cats discriminate between cholecalciferol and ergocalciferol.

A comparison was made of the ability of ergocalciferol and cholecalciferol to elevate plasma concentrations of vitamin D and 25-hydroxyvitamin D in cats. Cholecalciferol, given as an oral bolus in oil, resulted in a rapid elevation of plasma concentration of cholecalciferol followed by a rapid decline. In contrast, 25-hydroxyvitamin D concentration in plasma increased until day 3 after administration and remained elevated for a further 5 days. When 337 microg of both cholecalciferol and ergocalciferol in oil were given as an oral bolus to 10 cats, the peak plasma concentrations of cholecalciferol and ergocalciferol occurred at 8 or 12 h after administration. Peak concentrations of cholecalciferol were over twice those of ergocalciferol (570 +/- 80 vs. 264 +/- 42 nmol/l). The area under the curve 0-169 h for cholecalciferol was also more than twice that for ergocalciferol. When ergocalciferol and cholecalciferol were administered in a parenteral oil-based emulsion, higher concentrations of 25-hydroxyvitamin D3 than 25-hydroxyvitamin D2 were maintained in plasma. When both vitamins were included in the diet in the nutritional range, plasma concentrations of 25-hydroxyvitamin D2 were 0.68 of those of 25-hydroxyvitamin D3. Discrimination against ergocalciferol by cats appears to result from differences in affinity of the binding protein for the metabolites of the two forms of vitamin D. These results indicate that cats discriminate against ergocalciferol, and use it with an efficiency of 0.7 of that of cholecalciferol to maintain plasma 25-hydroxyvitamin D concentration.

Administration, Oral↗

Metabolism of dihydrotachysterol and 5,6-trans-cholecalciferol in the chick and the rat.

Dihydrotachysterol and 5,6-trans-cholecalciferol are biologically active analogues of cholecalciferol (vitamin D) with a similarity in steric structure to 1,25-dihydroxycholecalciferol, the active form of the vitamin. The question arises as to the nature of the active form of these analogues. High specific radioactivity (14)C- and (3)H-labelled forms of dihydrotachysterol and 5,6-trans-cholecalciferol and its 25-hydroxy derivative were synthesized and their metabolism was studied in chicks and rats. All these steroids were very rapidly metabolized compared with cholecalciferol; 20% of the dihydrotachysterol dose was excreted in bile in the first 24h, about 50% as a carboxylic acid derivative. Although polar metabolites were detected in tissues, no 1-hydroxy form was observed. Larger proportions of the parent steroid and its 25-hydroxy metabolite were detected in tissues compared with cholecalciferol, but no single metabolite was detected at the intracellular site of action of cholecalciferol. It is suggested that analogues of cholecalciferol will be biologically active if they possess a hydroxyl group in the same steric position as that at C-1 of cholecalciferol, with the greatest activity shown by those that also have a C-25 hydroxyl group. The implication of these findings for the chemical features necessary for binding to receptor proteins are briefly discussed.

Animals↗

Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.

When local treatments for prostate cancer have failed, and prostate-specific antigen (PSA) rises in the absence of symptoms, there is little consensus as to the best management strategy. Calcitriol has been shown to prolong the doubling time of PSA in this context, but near-toxic doses are required. We investigated the effect of the nutrient vitamin D (cholecalciferol), a biochemical precursor of calcitriol, on PSA levels and the rate of rise of PSA in these patients. Fifteen patients were given 2,000 IU (50 microg) of cholecalciferol daily and monitored prospectively every 2-3 mo. In 9 patients, PSA levels decreased or remained unchanged after the commencement of cholecalciferol. This was sustained for as long as 21 mo. Also, there was a statistically significant decrease in the rate of PSA rise after administration of cholecalciferol (P = 0.005) compared with that before cholecalciferol. The median PSA doubling time increased from 14.3 mo prior to commencing cholecalciferol to 25 mo after commencing cholecalciferol. Fourteen of 15 patients had a prolongation of PSA doubling time after commencing cholecalciferol. There were no side effects reported by any patient. Further study is needed to confirm this finding and to explore the potential therapeutic benefit of nutrient vitamin D in prostate cancer.

Administration, Oral↗

Influence of dietary cholecalciferol, calcium, and phosphorus on urinary calcium in commercial Leghorn hens.

An experiment was conducted to determine the influence of various dietary levels of cholecalciferol, Ca, and P on urinary Ca and pH, and on plasma concentrations of inorganic P (Pi) and total Ca (TCa) in commercial Leghorn hens. All hens were fed a layer diet containing 500 ICU of cholecalciferol/kg for 30 days and then allocated equally to treatment diets. Twelve treatment diets were in a 3 x 2 x 2 factorial arrangement that comprised three levels of cholecalciferol (0, 2,200, and 4,400 ICU/kg), two Ca levels (3.75 and 5.75%) and two P levels (.3% and .7%). After 9 days of feeding, blood (12 hens per time per treatment) and urine (6 hens per time per treatment) were sampled at 8 and 16 h after oviposition. Urinary Ca and plasma TCa concentrations increased (P less than .05) when dietary cholecalciferol level was increased from 0 to 2,200 ICU/kg, but did not change when cholecalciferol was increased from 2,200 to 4,400 ICU/kg. High levels of dietary Ca elevated (P less than or equal to .05) the urinary Ca concentration of hens fed the low-P treatments. Low levels of dietary P reduced plasma P and increased urinary Ca and pH at all levels of cholecalciferol and Ca; however, the magnitude of increases in urinary Ca were not uniform across all levels of cholecalciferol and Ca. Increases in urinary Ca resulting from low dietary P were relatively small when the diet lacked cholecalciferol, but was increased three- to fourfold when the diet contained adequate or excess levels of Ca and excess but not toxic levels of cholecalciferol.

Animals↗

Survival of vitamin D-deficient embryos: time and choice of cholecalciferol or its metabolites for treatment in ovo.

Vitamin D-deficient (-D) Japanese quail embryos [from hens fed 1,25-dihydroxycholecalciferol (1,25-(OH)2D3)] die at Day 15 of incubation from severe calcium deficiency. Single doses of 125 ng cholecalciferol, 600 ng 24,25-dihydroxycholecalciferol [24,25-(OH)2D3], or 100 ng 1,25-(OH)2D3 were found to increase hatchability when injected into eggs prior to incubation. Cholecalciferol could be used from 125 to 1,250 ng per egg with no detrimental effects on hatchability, whereas single doses of 1,25-(OH)2D3 lower or higher than 100 ng per egg reduced hatchability. Injection of 125 ng cholecalciferol per egg supported the hatching of -D embryos when eggs were treated as late as 10 days of incubation. Sharply reduced hatchability occurred when cholecalciferol was injected at Day 11 or 12 of incubation. Experiments designed to evaluate the physiological state of 1-day-old quail treated with a single dose of cholecalciferol metabolites in ovo prior to incubation revealed that chicks had hypocalcemia, reduced total calcium content, and a six- to sevenfold increase in renal 25-hydroxycholecalciferol-1-hydroxylase activity. On the other hand, chicks from eggs treated with cholecalciferol were relatively normal. It appears that cholecalciferol administered in ovo is the compound of choice for supporting sustained development of the skeleton, mobilization of shell calcium, and prevention of hypocalcemia, probably because cholecalciferol is utilized slowly as needed to support development of the chick skeleton.

Animals↗

Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells.

Epidemiological evidence suggests an inverse relationship between prostate cancer and serum vitamin D levels. We examined the ability of cholecalciferol (vitamin D(3)), a calcitriol precursor, to inhibit or reverse cellular changes associated with malignant transformation and invasion and explored its mechanisms of action. The RWPE2-W99 human prostate epithelial cell line, which forms slow-growing tumors in nude mice, was used because it mimics the behavior of the majority of primary human prostate cancers. Cholecalciferol, at physiological levels: (i) inhibited anchorage-dependent and -independent growth; (ii) induced differentiation by decreasing vimentin expression with a concomitant decrease in motility/chemotaxis; (iii) decreased MMP-9 and MMP-2 activity with concomitant decrease in invasion; and (iv) exerted its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptor-alpha (RXR-alpha), and androgen receptor (AR) in a dose-dependent manner. Furthermore, we found that RWPE2-W99 prostate cancer cells, similar to RWPE-1 cells (Tokar and Webber. Clin Exp Metast 2005; 22: 265-73), constitutively express the enzyme 25-hydroxylase CYP27A1 which is markedly up-regulated by cholecalciferol. Cholecalciferol has effects similar to those of calcitriol on growth, MMP activity, and VDR. The ability of CYP27A1 to catalyze the conversion of cholecalciferol to 25(OH)D(3) and of 25(OH)D(3) to calcitriol has been reported. RWPE2-W99 cells, similar to RWPE-1 cells, appear to have the rare ability to locally convert cholecalciferol to the active hormone calcitriol. Because it can inhibit cellular changes associated with malignant transformation and invasion, we propose that cholecalciferol may be an effective agent for the treatment of prostate cancer.

Calcitriol↗

Effect of cholecalciferol-enriched hen feed on egg quality.

Eggs are one of the most important sources of vitamin D in the human diet, and their vitamin D content can be further increased by adding more vitamin D to hen feed. To investigate this issue more closely, we performed two feeding experiments. In both, zero egg samples were collected while the hens were fed regular feeds with a vitamin D content of 1720 or 4280 IU/kg. In experiment 1, egg samples were collected 2, 4, 7, 9, 11, 13, 16, 23, and 30 days after beginning the high-cholecalciferol (11 200 IU/kg) feeding period. In experiment 2, samples were collected 2, 4, 6, 8, 13, 28, 56, 84, 112, 140, and 168 days after beginning the high-cholecalciferol (12 000 IU/kg) diet. The egg samples were then assayed for their cholecalciferol content, and some samples, also for the presence of 25-hydroxycholecalciferol by an HPLC method. Further, the vitamin D-fortified eggs were compared with the controls by a sensory evaluation, by conducting fatty acid and functional analyses (emulsion capacity, gel forming capacity, foaming properties) and by measuring eggshell strength. Because vitamin D can be toxic in high doses, we also performed histopathological tests on the hens at the end of experiment 2. The top cholecalciferol contents in egg yolk (ca. 30 microg/100 g) were reached 8-13 days from starting the high-cholecalciferol diet. After 112 days feeding the cholecalciferol content gradually decreased to ca. 22 microg/100 g. When added to eggs as described above, vitamin D did not affect their sensory or functional properties or their fatty acid composition. Moreover, the cholecalciferol levels used in this study appeared not to affect eggshell strength or to be harmful for hens.

Animal Feed↗

Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol.

BACKGROUND: The cholecalciferol inputs required to achieve or maintain any given serum 25-hydroxycholecalciferol concentration are not known, particularly within ranges comparable to the probable physiologic supply of the vitamin. OBJECTIVES: The objectives were to establish the quantitative relation between steady state cholecalciferol input and the resulting serum 25-hydroxycholecalciferol concentration and to estimate the proportion of the daily requirement during winter that is met by cholecalciferol reserves in body tissue stores. DESIGN: Cholecalciferol was administered daily in controlled oral doses labeled at 0, 25, 125, and 250 micro g cholecalciferol for approximately 20 wk during the winter to 67 men living in Omaha (41.2 degrees N latitude). The time course of serum 25-hydroxycholecalciferol concentration was measured at intervals over the course of treatment. RESULTS: From a mean baseline value of 70.3 nmol/L, equilibrium concentrations of serum 25-hydroxycholecalciferol changed during the winter months in direct proportion to the dose, with a slope of approximately 0.70 nmol/L for each additional 1 micro g cholecalciferol input. The calculated oral input required to sustain the serum 25-hydroxycholecalciferol concentration present before the study (ie, in the autumn) was 12.5 micro g (500 IU)/d, whereas the total amount from all sources (supplement, food, tissue stores) needed to sustain the starting 25-hydroxycholecalciferol concentration was estimated at approximately 96 micro g (approximately 3800 IU)/d. By difference, the tissue stores provided approximately 78-82 micro g/d. CONCLUSIONS: Healthy men seem to use 3000-5000 IU cholecalciferol/d, apparently meeting > 80% of their winter cholecalciferol need with cutaneously synthesized accumulations from solar sources during the preceding summer months. Current recommended vitamin D inputs are inadequate to maintain serum 25-hydroxycholecalciferol concentration in the absence of substantial cutaneous production of vitamin D.

Administration, Oral↗

Studies to determine whether an interaction exists among boron, calcium, and cholecalciferol on the skeletal development of broiler chickens.

Two experiments were designed to determine the effect of dietary boron on broiler cockerels and four experiments were conducted to determine whether an interaction exists among dietary boron, cholecalciferol, and calcium. The parameters measured were weight gain, feed efficiency, tibia bone ash, rickets, tibial dyschondroplasia, and plasma minerals. All experiments were conducted with tibial dyschondroplasia-inducing basal diets fed to broiler cockerels from 1 to 16 days of age. Experiments 1 and 2 had four levels of dietary boron (0, 20, 40, and 80 mg/kg (Experiment 1) and 0, 5, 10, and 20 mg/kg (Experiment 2). Boron had no effect on weight gain, feed efficiency, or plasma minerals in either experiment. In Experiment 2, increasing levels of boron had no influence on tibial dyschondroplasia but did exert a quadratic effect on bone ash with 5 and 10 mg/kg boron increasing bone ash. In Experiment 1, bone ash and the incidence of tibial dyschondroplasia were unaffected, but the severity of tibial dyschondroplasia linearly increased by increasing boron levels. Experiments 3 to 6 had a 2 x 2 x 2 factorial arrangement of treatments with calcium at .65 and .90%, cholecalciferol at 110 and 1,100 ICU/kg, and boron at 0 and 40 mg/kg (Experiments 3 to 5) or 0 and 3 mg/kg (Experiment 6). The higher levels of calcium and cholecalciferol improved weight gain, decreased the incidence of rickets, and decreased the incidence and severity of tibial dyschondroplasia. Feeding cholecalciferol at 1,100 ICU/kg increased plasma calcium and plasma dialyzable phosphorus and decreased plasma magnesium. Calcium at .90% had no effect on plasma magnesium or plasma dialyzable phosphorus and increased plasma calcium only in Experiment 4. The only response to boron in Experiments 3 to 6 was a boron effect and a boron by cholecalciferol interaction on bone ash in Experiment 3, in which boron reduced bone ash at .65% calcium and 110 ICU/kg cholecalciferol. From these experiments, there is no indication that an interaction among boron, cholecalciferol, and calcium exists in broiler cockerels.

Animal Feed↗

Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial.

BACKGROUND: A recent meta-analysis found that cholecalciferol (vitamin D) should reduce falls by more than 20%. However, little is known about whether supplemental cholecalciferol plus calcium citrate malate will lower the long-term risk of falling in men, active older individuals, and older individuals with higher 25-hydroxyvitamin D levels. METHODS: We studied the effect of 3-year supplementation with cholecalciferol-calcium on the risk of falling at least once in 199 men and 246 women 65 years or older and living at home. Individuals received 700 IU of cholecalciferol plus 500 mg of calcium citrate malate per day or placebo in a randomized double-blind manner. Subjects were classified as less physically active if physical activity was below the median level. Low 25-hydroxyvitamin D levels were classified as those below 32 ng/mL (<80 nmol/L). RESULTS: In 3 years, 55% of women and 45% of men reported at least 1 fall. Mean +/- SD baseline 25-hydroxyvitamin D levels were 26.6 +/- 12.7 ng/mL (66.4 +/- 31.7 nmol/L) in women and 33.2 +/- 14.2 ng/mL (82.9 +/- 34.9) in men. Cholecalciferol-calcium significantly reduced the odds of falling in women (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.30-0.97), but not in men (OR, 0.93; 95% CI, 0.50-1.72). Fall reduction was most pronounced in less active women (OR, 0.35; 95% CI, 0.15-0.81). Baseline 25-hydroxyvitamin D level did not modulate the treatment effect. CONCLUSIONS: Long-term dietary cholecalciferol-calcium supplementation reduces the odds of falling in ambulatory older women by 46%, and especially in less active women by 65%. Supplementation had a neutral effect in men independent of their physical activity level.

Accidental Falls↗

Calcium and inorganic phosphorus metabolism in naked mole rats Heterocephalus glaber is only indirectly affected by cholecalciferol.

Naked mole rats seem to be naturally deficient in cholecalciferol yet exhibit net calcium and inorganic phosphorus absorption efficiencies that approach a physiological maximum (i.e., exceed 94%). Oral supplementation with cholecalciferol therefore does not markedly enhance the efficiency of gastrointestinal absorption of these minerals, but rather exerts indirect effects on mineral metabolism by increasing food intake (1.7x) from 3.6 +/- 0.4 to 6.2 +/- 0.3 g/100 g body wt day-1. This, in turn, results in a concomitant increase in the daily rate of calcium absorption from 2.9 +/- 0.3 to 4.4 +/- 0.4 (mmol/100 g body wt day-1) and inorganic phosphorus absorption from 4.5 +/- 0.4 to 7.9 +/- 0.4 (mmol/100 g body wt day-1) with cholecalciferol supplementation. Excretion of calcium decreases from 2.9 +/- 0.5 to 1.2 +/- 0.4 mumol/100 g body wt day-1 with cholecalciferol supplementation whereas inorganic phosphorus excretion is unchanged (4.3 +/- 0.9 to 4.3 +/- 1.2 mumol/100 g body wt day-1), to give a positive mineral balance, without any evident pathology. Indeed serum calcium (2.3 +/- 0.1 vs 2.5 +/- 0.1 mmol/liter) and inorganic phosphorus (1.5 +/- 0.3 vs 1.6 +/- 0.2 mmol/liter) concentrations remain tightly regulated irrespective of vitamin D3 status. Mineral balance in naked mole rats is concluded not to be directly influenced by cholecalciferol, rather it may be affected by pleiotropic actions of cholecalciferol on gut function.

Animals↗

Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells.

The 20-30 year latency period for prostate cancer provides an important opportunity to prevent the development of invasive cancer. A logical approach for chemoprevention to reduce incidence is to identify agents, such as, vitamin D, which can inhibit cell proliferation and induce differentiation, are safe, and readily available to the public at low cost. Epidemiological evidence suggests that vitamin D deficiency is associated with increased risk for prostate cancer. We examined the ability and mechanisms of action of cholecalciferol (vitamin D(3)), a precursor of the most biologically active hormone calcitriol, to block or reverse premalignant changes. The immortalized, non-tumorigenic, RWPE-1 human prostate epithelial cell line, was used. Results show that cholecalciferol, at physiological levels: (i) inhibits anchorage-dependent growth (ii) induces differentiation by increasing PSA expression and (iii) exerts its effects by up-regulating vitamin D receptor (VDR), retinoid-X receptors (RXRs), and androgen receptor (AR). Furthermore, we discovered that human prostate epithelial cells constitutively express appreciable levels of 25-hydroxylase CYP27A1 protein, the enzyme which catalyzes the conversion of cholecalciferol to 25(OH)D(3), and that CYP27A1 is up-regulated by cholecalciferol. Recent studies show that human mitochondrial CYP27A1 can also catalyze 1alpha-hydroxylation of 25(OH)D(3) to calcitriol. The presence of 25-hydroxylase in human prostate epithelial cells has not previously been shown. Since human prostate epithelial cells have the necessary enzymes and the rare ability to locally convert cholecalciferol to the active hormone calcitriol, we propose that they are a prime target for chemoprevention of prostate cancer with cholecalciferol whose safety is well established as a supplement in vitamins and fortified foods.

Calcitriol↗

Determination of phylloquinone and cholecalciferol encapsulated in granulates formed by melt extrusion.

Vitamin K1 (phylloquinone) and vitamin D3 (cholecalciferol) play a dominant role in bone metabolism. Both vitamins are sensitive to ultraviolet radiation, oxygen and other environmental influences. For this reason a special extrusion technology was developed, that enables an encapsulation of these sensitive substances in a matrix of carbohydrates and hydrogenated carbohydrates. To exclude decomposition products possibly originating under process conditions quantitative analysis was carried out by HPLC/UV using a modified method based on United States Pharmacopoeia. Under the used chromatographic conditions it has to be possible to separate cis-phylloquinone, trans-phylloquinone and phylloquinone 2,3-oxide, as well as pre-cholecalciferol, cis-cholecalciferol and trans-cholecalciferol. A silica column as stationary phase and a mixture of n-hexane and 1-amyl alcohol as mobile phase were used for quantification. UV detection ensued at 254 nm. A linear relationship between peak area and concentration was found over almost two orders of magnitude for cis-phylloquinone, trans-phylloquinone and cholecalciferol. The detection limits (S/N 3) on column were 0.1 microg for phylloquinone and 0.4 microg for cholecalciferol. Analytical results showed that the vitamins were encapsulated sufficiently in the used carbohydrate matrix and that they were protected against environmental influences. After granulation process all of the samples tested met the pharmacopoeial requirements.

Biotechnology↗

Recovery of impaired K+ channels in mesenteric arteries from spontaneously hypertensive rats by prolonged treatment with cholecalciferol.

1. The mechanism responsible for blood pressure reduction in spontaneously hypertensive rats (SHR) after prolonged cholecalciferol treatment was studied. Two-week treatment of SHR with 0.125 mg cholecalciferol kg-1 body weight per day orally caused significant reductions of systolic blood pressure and of the resting perfusion pressure of the mesenteric vascular bed at constant flow. 2. In addition, the treated animals presented a normalization of the maximum vasoconstriction response to noradrenaline and a reduction of the maximum effect of the adrenaline concentration-response curves. This latter effect probably was due to recovery of the impaired Ca(2+)-dependent K+ channels coupled to alpha 2-adrenoceptors since it was prevented by apamin. 3. The treatment with cholecalciferol also normalized the smooth muscle cell membrane potential of de-endothelialized mesenteric arteries of SHR and their hyperpolarizing responses to alpha 2-adrenergic agonists, which were depressed in untreated SHR. 4. In mesenteric rings with endothelium, alpha 2-adrenergic agonists caused similar hyperpolarizing responses in the SHR and in normotensive Wistar (NWR) and Wistar Kyoto (WKY). In non cholecalciferol-treated SHR the hyperpolarizing mediator involved in this effect was NO, while in NWR it was the endothelium-derived hyperpolarizing factor (EDHF). After cholecalciferol treatment, the hyperpolarization induced by alpha 2-adrenergic agonists in SHR smooth muscle cells was mediated by EDHF, as in NWR. 5. Our results indicate that the hypotensive effect of cholecalciferol in the SHR is probably due to the normalization of vascular reactivity, by restoring the functioning of apamin- and ATP-sensitive K+ channels located in the vascular smooth muscle cell membrane, which are impaired in the SHR.

Animals↗

Effects of cholecalciferol on the translocation of calcium by non-everted chick ileum in vitro.

An apparatus is described that allows perfusion of a non-everted segment of intestine in vitro and the study of the accumulation of substances within the mucosal cells. The translocation of Ca(2+) by rachitic-chick ileum and the effect of pretreatment with cholecalciferol was investigated, with the following conclusions. (1) Entry of Ca(2+) across the microvilli into mucosal cells is by diffusion; it does not require metabolic energy or the presence of any other inorganic ions. (2) Pretreatment of the chick with cholecalciferol causes increased permeability of the microvillus to Ca(2+) in both directions (lumen to cell, cell to lumen). The increased transport brought about by cholecalciferol in vivo can be partially mimicked by sodium dodecyl sulphate added in vitro. (3) The sign and the magnitude of the electrical potential difference prevailing across the ileum does not influence Ca(2+) transport. (4) Exit of Ca(2+) from the mucosal cell is temperature-sensitive, requires metabolic energy and Na(+). (5) Pretreatment with cholecalciferol caused increased movement of Ca(2+) out of the cell across the basement membranes. This effect of cholecalciferol given in vivo could be markedly increased by the presence of dicyclohexylcarbodi-imide in the perfusion fluid. These observations suggested that cholecalciferol increased Ca(2+) entry (and exit) at the mucosal surface and also caused Ca(2+) to be more available to the pump at the serosal surface.

Anaerobiosis↗

Characteristics of the rat liver microsomal enzyme system converting cholecalciferol into 25-hydroxycholecalciferol. Evidence for the participation of cytochrome p-450.

Properties of the rat hepatic cholecalciferol 25-hydroxylase have been studied. An assay system has been developed in which 25-hydroxycholecalciferol production is linear for at least 2h in both homogenates and microsomal fraction. Furthermore, the initial reaction velocity is linearly related to the amount of liver tissue or microsomal fraction. This enzyme system also metabolizes an analogue of cholecalciferol, namely dihydrotachysterol 3, into 25-hydroxydihydrotachysterol 3. The 25-hydroxylase is in the microsomal fraction and not in mitochondria. It has a Km of 44 nM for cholecalciferol and 360 nM for dihydrotachysterol 3. Its activity is not altered by dietary concentrations of calcium and phosphorus. Vitamin D-deficient rats have higher activities of the hepatic 25-hydroxylase than those receiving 25 ng of cholecalciferol daily. The 25-hydroxylase is inhibited by metyrapone. An atmosphere of CO/O2 (9:1, v/v) inhibits the reaction by 87%. This inhibition is partially reversed by white light. Additionally, cholecalciferol and 25-hydroxycholecalciferol competitively inhibit aminopyrine demethylase. These results support the idea that the cholecalciferol 25-hydroxylase is a cytochrome P-450-dependent mono-oxygenase.

Animals↗